

NILG-AML 00-01 Study

High Risk (HR):

- Late CR
- FLT3 ITD +
- K adverse
- S-AML

HR

Allo SCT

ICE

CR

IC

NR

SPLIT



A8

SC harvest

SR

no SC
harvest

A20

A20

A20

SC

SC

SC

CD34+: $1-2 \times 10^6/\text{kg}$,
G-CSF

A10

A10

ICE:

Idarubicin 12 mg/sqm dd 1-3

Ara-C 100mg/sqm/bd dd 1-7

VP16 100mg/sqm/bd dd 1-5

IC:

Idarubicin 10mg/sqm dd 1-3

Ara-C 100mg/sqm/bd dd 1-7

SPLIT:

Idarubicin 17.5 mg/sqm dd 1,8

Ara-C 3* g/sqm/bd dd 2,3 and 9,10

*2 >55 yy

A8:

Ara-C 1g/sqm/bd dd 1-4

A10: Idarubicin 8 mg/sqm d 1

Ara-C 1g/sqm/bd dd 1-5

A20: Idarubicin 10 mg/sqm dd 1,2

Ara-C 2g/sqm/bd dd 1-5

>70yy: HDAC at reduced dose (total dose 38g/sqm or 54g/sqm)

Figure S1. Treatment Plan.

Table S1. Characteristics of 366 AML patients, incidence of molecular mutations (*NPM1* and *FLT3*).

Overall		Number (%)
		366
Sex	male	203 (55.5)
	female	163 (44.5)
<i>NPM1</i>	mutated	132/327 (40.4)
	unmutated	195/327 (59.6)
	not available	39/366 (10.6)
<i>FLT3</i>	mutated	98/352 (27.8)
<i>FLT3</i> -ITD	mutated	65/352 (18.5)
	unmutated	287/352 (81.5)
	not available	14/366 (3.8)
<i>FLT3</i> -TKD	mutated	33/316 (10.4)
	unmutated	28/316 (8.9)
	not available	50/366 (13.6)
<i>NPM1/FLT3</i> -ITD	<i>NPM1</i> m/ <i>FLT3</i> -ITD wt	73/138 (52.9)
	<i>NPM1</i> m/ <i>FLT3</i> -ITD m	38/138 (27.5)
	<i>NPM1</i> wt/ <i>FLT3</i> -ITD m	27/138 (18.6)
	favorable	38 (10.4)
Karyotype Risk Classification*	intermediate	265 (72.4)
	adverse	59 (16.1)
	not available	4 (1.1)

Abbreviations: wt: wild-type; m: mutated.

Notes: *according to MRC [22].